Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock Has Average Target Price of $14.00

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) have been given a consensus rating of “Hold” by the ten analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $14.00.

Several research analysts have recently weighed in on the stock. Leerink Partners set a $4.00 target price on shares of Tenax Therapeutics in a research report on Tuesday, August 11th. UBS Group cut Tenax Therapeutics to a “neutral” rating in a research report on Monday, August 31st. Chardan Capital downgraded Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Tuesday, August 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tenax Therapeutics in a research report on Thursday, September 10th. Finally, Weiss Ratings lowered shares of Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, September 14th.

Get Our Latest Report on Tenax Therapeutics

More Tenax Therapeutics News

Here’s some of the latest news about TENX:

  • Negative Sentiment: The lawsuit alleges securities-law violations, including that Tenax and executives made misleading statements about the Phase 3 LEVEL study of its drug candidate TNX-103—among them, claims that the study was enriched with patients most likely to respond. These are allegations, not proven findings, but the litigation may add legal and reputational uncertainty for the company. Pomerantz class-action filing announcement Investor alert describing allegations
  • Negative Sentiment: Multiple law firms publicized the case and solicited investors to seek lead-plaintiff status, amplifying attention around the dispute. The deadline to seek that role is December 28, 2026. Rosen investor notice

Tenax Therapeutics Stock Performance

Shares of NASDAQ:TENX opened at $1.42 on Wednesday. The company has a market capitalization of $64.67 million, a PE ratio of -1.02 and a beta of 0.99. The stock has a fifty day moving average of $1.77 and a 200-day moving average of $9.29. Tenax Therapeutics has a one year low of $1.31 and a one year high of $19.40.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.04. As a group, research analysts forecast that Tenax Therapeutics will post -1.27 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc bought 900,000 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was bought at an average price of $1.78 per share, for a total transaction of $1,602,000.00. Following the transaction, the insider directly owned 6,524,151 shares in the company, valued at $11,612,988.78. This represents a 16.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have purchased 3,682,899 shares of company stock valued at $6,388,279. 10.81% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tenax Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its holdings in shares of Tenax Therapeutics by 128.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 627,023 shares of the specialty pharmaceutical company’s stock worth $1,185,000 after purchasing an additional 352,077 shares during the period. Marshall Wace LLP raised its position in Tenax Therapeutics by 203.9% in the 3rd quarter. Marshall Wace LLP now owns 1,779,564 shares of the specialty pharmaceutical company’s stock worth $3,363,000 after purchasing an additional 1,193,986 shares during the last quarter. Gabelli Funds LLC bought a new position in Tenax Therapeutics in the 3rd quarter valued at $28,000. Russell Investments Group Ltd. increased its stake in shares of Tenax Therapeutics by 1,005.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 22,667 shares of the specialty pharmaceutical company’s stock valued at $43,000 after buying an additional 20,616 shares during the period. Finally, Alps Advisors Inc. raised its position in shares of Tenax Therapeutics by 82.8% during the third quarter. Alps Advisors Inc. now owns 49,225 shares of the specialty pharmaceutical company’s stock worth $93,000 after acquiring an additional 22,301 shares during the last quarter. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition involving elevated pressure in the lung’s blood vessels and impaired heart function. The company’s lead program is levosimendan, a drug being developed in different formulations for PH-HFpEF. Tenax has described its development program as including oral, intravenous and subcutaneous formulations.

Featured Stories

Analyst Recommendations for Tenax Therapeutics (NASDAQ:TENX)

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.